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Early-stage lung cancer refers to patients presenting with
clinical stages I and II non-small-cell lung cancer (NSCLC)
according to the TNM classification. They represent approxi-
mately 20–25% of incident cancer cases in most population-
based cancer registries, and radical surgical resection is con-
sidered the treatment of choice in operable and fit patients [1].
Although no prospective, randomised trial exists to compare
surgery versus radiotherapy in the treatment of early-stage
NSCLC, surgical resection has traditionally been considered
the treatment of choice. Markedly improved survival rates
are reported in surgical series in comparison to patients
who did not undergo surgical resection for a variety of rea-
sons [2]. This abstract will address some of the challenges
of novel treatment options in these patients.
With low-dose computed tomography (CT) scan screening
becoming the new standard of early detection of lung cancer,
physicians and surgeons will be confronted with an increase
in T1a lung cancer, disguised as non-calcified nodules.
Although it is tempting to proceed to a parenchyma-sparing
resection for issues of functional operability, the risk of local
recurrence and inadequate intraoperative lymph-node stag-
ing should not be neglected. Whether some of these lesions
can be treated by so-called sublobar resection – consisting
of either anatomical segmentectomy or wedge excision – is
currently the subject of intensive investigation by appropriate
randomised trials. For a limited resection to be oncologically
valid, a precise pre- and intraoperative diagnosis is impera-
tive. In terms of preoperative diagnosis, specific criteria on
chest CT as percentage ground-glass opacity (GGO), tumour
shadow disappearance rate and histogram analysis have been
shown to have a high predictive value[3]. Three similar trials –
JCOG 0802 in Japan, CALGB 140503 in North America and IEO
S638/311 in Italy – are currently enroling patients, and collab-
oration is highly regarded [4,5].
More tailored, personalised surgical therapy has recently
been introduced. Quality-of-life parameters and surgical
quality indicators become increasingly important to deter-1359-6349/$ - see front matter Copyright  2013 ECCO - the European
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cedure. International databases currently collect extensive
surgical data, allowing more precise calculation of mortality
and morbidity according to predefined risk factors. Centrali-
sation of care has been shown to improve results [6].
Functionally inoperable patients are nowadays proposed
stereotactic ablative body radiotherapy (SABR), in which hyp-
ofractionated doses are administered over a short period of
time [7,8]. Although lung-cancer-specific time-to-event out-
come data seem very promising, unusual late toxicity is
increasingly being reported, and there is concern regarding
the inclusion of variable fractions of non-pathologically pro-
ven non-calcified nodules [9]. Clearly, before extrapolating
these results to functionally operable patients, large random-
ised trials with an unequivocal non-inferiority design should
be carried out [10]. Other radiotherapeutic techniques in
development to improve local control with minimal pulmon-
ary toxicity are the application of different breath control de-
vices and the introduction of hadron/proton therapy.
Radiofrequency ablation is another way of tackling pul-
monary masses and nodules whereby a transthoracic radiop-
robe is inserted under CT guidance, allowing for a subsequent
‘cooking’ with electromagnetic energy. The technique is well
known in the treatment of primary liver cancer and metasta-
ses, and several uncontrolled series have been reported in a
mixed series of patients with primary lung cancer and lung
metastases [11]. However, the technique lacks standardisa-
tion and long-term results, but is promising for centres which
cannot afford SABR. There are currently no ongoing random-
ised trials [12]. An endobronchial application is certainly
promising.
Adjuvant chemotherapy is the present standard of care in
completely resected stages pII and III NSCLC, albeit toxicity is
considerable and the observed improvement in outcome
modest. Patient selection using molecular and biological bio-
markers and signatures is likely to increase the fraction of pa-
tients benefiting from it. The large BIO-IALT study has
described a number of prognostic and predictive factors,
although recent reports challenge the accuracy of theCanCer Organisation. All rights reserved.
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regarding tumour biomarkers concerns methodology. Tech-
niques for carrying out the test, the reagents used, methods
used to score/quantify the results, the analysis and interpre-
tation of the results are all critical yet prone to variability and
error. Some are more subjective than others; many are simple
and readily available, others are complex, expensive and less
accessible. Complexity does not guarantee accuracy, greater
reliability or relevance. In terms of biomarker testing of tu-
mour samples, the handling and processing of the tissues
prior to testing is of critical importance yet difficult to stan-
dardise, but these factors are often ignored or overlooked [15].
Biomarkers might be selected for patients preferably trea-
ted with agents targeted at hallmark pathways of oncogene-
sis: e.g. sustained proliferation, angiogenesis and avoiding
immune destruction. Trials investigating the efficacy of adju-
vant epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors, vascular endothelial growth factor (VEGF) inhibi-
tors or vaccines against melanoma antigen (MAGE) are cur-
rently ongoing, and their results are expected to alter
clinical practice [16,17].
Although neoadjuvant chemotherapy is better tolerated
and its added value to outcome is similar to that of adjuvant,
its widespread use suffers from a low rate of pathological
remission, which is a precondition for a lesser resection to
be carried out. Window-of-opportunity trials with neoadju-
vant targeted agents and biological imaging are promising
[18]. They have so far not been conducted in a biomarker-se-
lected population.
The role of postoperative radiotherapy is currently limited
to non-radically resected cases, although there are uncon-
trolled observations of its efficacy in subgroups of completely
resected patients. In the ongoing randomised LUNGART trial,
its role is explored in patients with clinical or pathological N2
disease [19].
An important handicap in present-day patient selection is
the inaccuracy of clinical staging. Half or more of clinically
staged patients are up- or down-staged at surgery [20]. Posi-
tron emission tomography–CT (PET–CT) scan and minimally
invasive mediastinal ultrasound techniques are expected to
improve on this figure and result in a stage shift.
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